

[Ceftriaxone](#)

Statut de médicament essentiel

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.2. Watch group antibiotics](#)

Codes ATC: [J01DD04](#)

Indication

Gonococcal infection Code ICD11: [1B0Z](#)

INN

Ceftriaxone

Type de médicament

Chemical agent

Groupes d'antibiotiques

[WATCH](#)

Type de liste

Liste de base

Additional notes

Do not administer with calcium and avoid in infants with hyperbilirubinaemia.

Formulations

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) (EML) ; 2 g in vial powder for injection (as sodium salt)

Historique des statuts LME

Ajouté pour la première fois en 2017 ([TRS 1006](#))

Modifié en 2023 ([TRS 1049](#))

Sexe

Tous

Âge

Adolescents et adultes

Limite d'âge

> 41 weeks corrected gestational age

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Ceftriaxone](#)

DrugBank

[Ceftriaxone](#)

Recommandation du comité d'experts



In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - replacing the oral liquid formulation of azithromycin (200 mg/5 mL) with powder for oral liquid 200 mg/5 mL on the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.

Recommandations de la LME : Gonococcal infection

Premier choix

Second choix

Premier choix

[ceftriaxone](#)

Second choix

[cefixime](#)

[spectinomycin](#)

[gentamicin](#)